Melanoma Matters

Summary

*Warning* with apologies! There is a change in sound at 11:11 mark that might necessitate a lower volume output.

Hosts James Larkin has a beef with the first word of the cemiplimab + fianlimab JCO publication. He's living vicariously through Sapna's snowboarding plans for the season (if the record high temps ever stop). They continue to struggle with Farenheit to Centrigrade conversion.

In this episode of Melanoma Matters, James and Sapna discuss the recent publication on cemiplimab and fianlimab, focusing on their efficacy in various patient cohorts, particularly those who are PD-1 naive. They discuss if all LAG-3 antibodies are created equal, and one host is busted for not reading the Supplementary Appendix to the publication.

Keywords

melanoma, cemiplimab, fianlimab, LAG-3, PD-1, cancer therapy, clinical trials, efficacy, adverse events, immunotherapy

Takeaways

• Objective response rates are promising in various cohorts.
• Semiplimab and Thiamlimab show efficacy in PD-1 naive patients.
• The study highlights the need for larger randomized trials.
• Comparative efficacy of LAG-3 therapies remains to be seen.
• Adverse events like infusion reactions are noteworthy.
• The conversation emphasizes the importance of ongoing research.
• Understanding patient selection criteria is crucial for interpreting results.
• The hosts discuss the implications of the findings for future treatments.
• There is excitement about the potential of these new therapies.
• The episode underscores the evolving landscape of melanoma treatment.
• ALWAYS READ THE SUPPLEMENTARY APPENDIX

Titles

Understanding LAG-3 Therapies in Melanoma

The Promise of LAG-3 in Advanced Melanoma

Sound Bites

"Objective response rate in all these cohorts looks good"

"This is a paper about a novel (anti) LAG- 3 + PD-1 combination"

"The objective response rate is topping 50%"

Chapters

00:00 Introduction

04:56 Discussion on Cemiplimab and Fianlimab

07:48 Exploring Phase One Trial Data

10:56 Comparative Analysis of LAG-3 Therapies

11:11 *Warning* Volume / Sound Change

14:16 Understanding Patient Cohorts and Response Rates

16:50 Comparative Analysis of Treatment Options

20:10 Safety and Adverse Effects of New Combinations

23:11 Future Trials with This Combination

Summary

Left siding, Starfishing, and Superstitions! We make a hidden shoutout to Owen and a subtle callout to Zayd ... if you're listening

In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin delve into the Keynote 006 study, exploring its implications for melanoma treatment, long-term follow-up, and patient outcomes. The conversation highlights the importance of understanding CR versus PR in treatment and the need for better data collection on re-treatment. The episode concludes with reflections on the challenges of conducting such extensive research and the importance of collaboration in the field.

Keywords

melanoma, immunotherapy, pembrolizumab, Keynote 006, patient outcomes, superstitions, sleep habits, treatment duration, toxicity, CR vs PR, PFS vs TTP

Takeaways

• The Keynote 006 study provides valuable data on melanoma treatment.
• Long-term follow-up is crucial for understanding treatment efficacy.
• Re-treatment with pembrolizumab can be beneficial for certain patients.
• Understanding the difference between CR and PR is essential in treatment discussions.
• Toxicity profiles of treatments need to be monitored over time.
• Time to progression is a more relevant metric than PFS in some cases.
• Collaboration among researchers is vital for advancing melanoma treatment.

Sound Bites

"It's better to have a CR than have a PR."

"We need to stop doing PFS in long-term follow-ups."

"Patients are dying of other causes, not melanoma."

Chapters

00:00 Introduction and Greetings

03:25 Left side and Starfish

06:43 Superstitions and Their Impact on Behavior

09:35 Keynote 006 Study Overview

12:26 Long-term Follow-up and Treatment Insights

15:38 Re-treatment and Patient Outcomes

18:24 CR vs PR and Treatment Duration

25:07 Final Thoughts and Acknowledgments

28:21 Call to fellows (hearing us, Zayd?)

36:14 PFS v. TTP

Summary

More stories about medical emergencies! In this conversation, James Larkin and Sapna Patel discuss the complexities of tumor dynamics in patients treated with pembrolizumab beyond disease progression. They share personal anecdotes about medical emergencies on flights, which lead into a deeper exploration of treatment strategies and clinical trial methodologies. The discussion emphasizes the importance of understanding patient responses to treatment, the limitations of traditional assessment tools like RESIST, and the need for careful consideration in trial designs to avoid premature conclusions about new therapies.

Keywords

tumor dynamics, pembrolizumab, treatment beyond progression, medical emergencies, clinical trials, cancer treatment, immunotherapy, patient care, melanoma, PD-1

Takeaways

Treatment beyond progression can yield clinical benefits.

RECIST criteria may not accurately reflect patient responses to immunotherapy.

Understanding disease trajectory is crucial in treatment decisions.

Clinical trials must be designed to account for patient variability.

The importance of patient monitoring during treatment is emphasized.

AI could revolutionize tumor assessment in clinical practice.

Caution is advised when interpreting early trial results.

Stepwise progression in trial design can save resources.

Titles

Innovations in Tumor Assessment

Cautionary Tales in Cancer Research

Chapters

00:00 Medical Emergencies on Flights

10:46 Treatment Beyond Progression in Cancer

16:49 Clinical Trials and Patient Outcomes

26:47 Cautionary Tales in Cancer Treatment

Summary

In this episode of Melanoma Matters, Sapna and James discuss the importance of looking at Figure 1. They talk about in-flight medical emergencies, and James recalls a scene of carnage ... "blood everywhere."

They delve into the complexities of mucosal melanoma, discussing its unique characteristics, treatment options, and the latest research findings. They share personal anecdotes from their medical experiences, emphasizing the importance of understanding the nuances of this melanoma subtype. The conversation covers the efficacy of checkpoint inhibitors, the significance of various studies, and considerations for adjuvant and neoadjuvant therapies. The hosts also highlight the need for tailored approaches in treating mucosal melanoma patients, given the disease's heterogeneity and geographical variations.

Keywords

Mucosal Melanoma, Checkpoint Inhibitors, Adjuvant Therapy, Neoadjuvant Therapy, Oncology, Cancer Treatment, Medical Stories, Clinical Trials, Patient Care, Melanoma Research

Takeaways

Mucosal melanoma is a unique subtype that requires specific attention.

Checkpoint inhibitors have shown efficacy in treating mucosal melanoma.

Understanding geographical variations is crucial in melanoma treatment.

Clinical trials often exclude mucosal melanoma patients, impacting data.

Adjuvant therapy may be beneficial but is not universally applicable.

Neoadjuvant therapy could be a reasonable option for certain patients.

Response rates vary significantly based on the anatomical site of the melanoma.

Patient performance status plays a critical role in treatment decisions.

The importance of thorough data collection in clinical trials cannot be overstated.

Personal anecdotes from physicians highlight the unpredictable nature of medical emergencies.

Titles

Emergency Medical Stories: A Doctor's Perspective

Comparative Studies in Mucosal Melanoma Treatment

Sound Bites

"I think we actually missed this figure."

"Always look at Figure 1."

Chapters

00:00 Introduction to Mucosal Melanoma

05:21 Anecdotes from the Medical Field

08:19 Understanding Mucosal Melanoma

14:25 Sapna and James look at Figure 1

20:21 Comparative Analysis of Studies

26:30 Adjuvant and Neoadjuvant Therapies for Mucosal Melanoma

Summary

James' favorite moments from #ESMO24 include footie and a not-so-chance encounter with NEJM Editor-in-Chief, Eric Rubin.

In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin discuss the Relativity 020 study, which focuses on Nivo Rela after PD-1 exposure in melanoma patients. They reflect on their experiences at ESMO, including networking and memorable moments, before diving into the details of the study, including patient cohorts, treatment efficacy, and the challenges faced in clinical trials. The conversation also touches on the role of CTLA-4 therapies and the complexities of treatment sequencing in melanoma care.

Keywords

melanoma, ESMO, Relativity 020, Nivo Rela, PD-1, CTLA-4, clinical trials, patient access, immunotherapy, oncology

Takeaways

The Relativity 020 study explores Nivo Rela after PD-1 exposure in melanoma.

Networking at ESMO is crucial for sharing insights and experiences.

Patient access to treatments is a significant challenge in clinical trials.

The efficacy of Nivo Rela in heavily pretreated patients is limited.

CTLA-4 therapies show low response rates in PD-1 refractory patients.

Understanding treatment sequences is essential for optimizing patient outcomes.

The importance of academic trials in addressing knowledge gaps in melanoma treatment.

Elevated LDH levels are a concerning biomarker in treatment response.

Collaboration among investigators is vital for advancing melanoma research.

The conversation highlights the need for ongoing research and trials in melanoma.

Chapters

00:00 Introduction and ESMO Highlights

03:30 Reflections on ESMO 2024

06:21 The Relativity 020 Study Overview

09:17 Patient Perspectives and Clinical Trials

12:20 Challenges in European Clinical Trials

15:36 Efficacy of NIVO-RELA in Refractory Melanoma

18:40 Discussion on CTLA-4 Therapies

21:21 Future Directions in Melanoma Treatment

Summary

In this episode of Melanoma Matters, hosts James Larkin and Sapna Patel reflect on their experiences at ESMO 2024 and the importance of face-to-face meetings. But then James pops the balloon by commenting on the carbon footprint of the airplane travel. They go on to discuss the phase three trial comparing ipilimumab doses in melanoma and delve into the trial's design, results, and implications for clinical practice. The conversation also covers the significance of long-term follow-up data, the challenges of pooled analyses, and the need for improved clinical trial design to capture more nuanced survival data.

Keywords

melanoma, ipilimumab, clinical trials, ESMO, cancer treatment, immunotherapy, overall survival, phase three trial, patient care, research

Takeaways

The value of face-to-face meetings is irreplaceable.

The IP10 trial was crucial for understanding ipilimumab dosing.

Access to effective treatments can be limited by bureaucracy.

Long-term follow-up data is essential for understanding treatment efficacy.

Re-challenging with ipilimumab can be effective in certain cases.

Pooled analyses can provide insights but have limitations.

Clinical trial design should capture more than just overall survival.

Data quality varies between industry and academic studies.

Understanding the mechanisms of resistance is key to treatment.

Dosing strategies in immunotherapy require careful consideration.

Sound Bites

"My favorite is just being within vibrational energy of people you hold dear."

"We had a queue of patients waiting to go into the study."

"This study was really trying to answer in a prospective way."

Chapters

00:00 Introduction and Icebreaker Moments

03:41 Discussion on the Phase Three IP10 Trial

06:15 Trial Design and Results Overview

09:04 Clinical Implications and Treatment Access

12:01 Re-challenging with Ipilimumab

14:55 Long-term Follow-up and Survival Rates

18:07 The Importance of Data Quality in Trials

20:19 Conclusions and Final Thoughts

Summary

In this episode, James needs some sun cream! The conversation discusses the outcomes of post-recurrence systemic therapy following adjuvant checkpoint inhibitor treatment for resected melanoma in the Checkmate 238 trial. The study found that early recurrences were associated with worse outcomes compared to late recurrences. Patients who recurred early had shorter progression-free survival and overall survival compared to those who recurred later. The subsequent therapy received by patients varied, with some receiving chemotherapy, immunotherapy, or targeted therapy. The data on subsequent therapy were not well-categorized, making it difficult to draw definitive conclusions. The conversation highlights the challenges of treating patients who recur despite adjuvant therapy and the need for further research in this area.

Keywords

melanoma, adjuvant therapy, recurrence, systemic therapy, checkpoint inhibitors, progression-free survival, overall survival, subsequent therapy

Takeaways

• Early recurrences in melanoma patients who received adjuvant checkpoint inhibitor therapy are associated with worse outcomes compared to late recurrences.
• The subsequent therapy received by patients varied, with some receiving chemotherapy, immunotherapy, or targeted therapy.
• The data on subsequent therapy were not well-categorized, making it difficult to draw definitive conclusions.
• Treating patients who recur despite adjuvant therapy remains a significant challenge in clinical practice.

Sound Bites

"Early recurrences in melanoma patients are a bad thing."

"Sensitivity to anti-PD-1 drugs is not black and white; there are gray zones."

"The subsequent therapy received by patients varied, with some receiving chemotherapy, immunotherapy, or targeted therapy."

Chapters

00:00 Introduction and Personal Experiences with Sunburns

05:00 Overview of Checkmate 238 and Outcomes after Recurrence

09:58 Early versus Late Recurrences and Treatment Outcomes

16:58 Analysis of Recurrence Patterns and Subsequent Therapies

23:58 Discussion on Anatomic Sites of Recurrence

29:27 Conclusion and the Importance of Further Research

30:30 Fact Check

31:54 The Search for Clinically Usable Biomarkers

32:20 Acknowledging Efforts

Summary

(Coach) Owen is in a seriously bad mood with James at the moment! But James is back in pull-up form and can do an impressive number of strict pull-ups...

In this episode, Sapna Patel and James Larkin discuss the LEAP 004 and LEAP 003 studies, focusing on the combination of lenvatinib and pembrolizumab in treating melanoma, particularly in patients who are refractory to PD-1 inhibitors. They explore the efficacy, safety, and implications of these studies, as well as the challenges in treatment guidelines and future directions for research in this area.

Keywords

melanoma, LEAP 004, lenvatinib, pembrolizumab, clinical trials, cancer treatment, efficacy, safety, guidelines

Takeaways

The LEAP 004 study showed a 21.4% response rate.

Lenvatinib is a multi-targeted VEGF receptor inhibitor with potential in melanoma.

The combination of lenvatinib and pembrolizumab may increase sensitivity to PD-1 inhibitors.

Toxicity is a significant concern with the lenvatinib and pembrolizumab combination.

LEAP 003 did not demonstrate an improvement in overall survival compared to pembrolizumab alone.

The efficacy of lenvatinib in melanoma is still being evaluated in refractory settings.

There is a need for further studies to understand the mechanisms of resistance to PD-1 therapy.

Guidelines for treatment may vary significantly between jurisdictions.

Patient perspectives on treatment and toxicity are crucial in clinical practice.

The future of lenvatinib and pembrolizumab in melanoma treatment remains uncertain.

Sound Bites

"What's your number of kilos you're deadlifting?"

"Lenvatinib has been around for a while."

"The unmet need we all know, which is anti PD-1 refractory melanoma."

Chapters

00:00 Introduction and Discussion of Deadlifting

03:31 Overview of Leap004 Study and Rationale for Lenvatinib

09:22 Promising Results in Leap004 Study

15:59 Discontinuation of Leap003 Trial

19:33 Challenges with Dosing and Toxicity of Lenvatinib

22:00 Uncertainty in the Use of Lenvatinib-Pembrolizumab in PD-1 Refractory Patients

Summary

On the heels of the great ESMO 2024 session with Toni Ribas, Inge Marie Svane, and Olivier Michielin James and Sapna discuss Prof Svane and Prof van Haanen's TIL trial, a significant study in melanoma treatment that explores the efficacy and safety of tumor-infiltrating lymphocyte (TIL) therapy compared to traditional treatments. They delve into the historical context of the trial, its design, the observed efficacy rates, potential side effects, and the implications of sex-based differences in treatment outcomes. The discussion highlights the importance of this trial in shaping future treatment strategies for melanoma and the need for further research in this area.

Keywords

TIL trial, melanoma, cellular therapy, immunotherapy, efficacy, toxicity, first-line treatment, sex-based differences

Takeaways

The TIL trial is a landmark study in melanoma treatment.

TIL therapy shows a near 50% response rate in patients.

The control arm of the trial has faced criticism.

TIL therapy is a viable strategy for patients after PD-1 exposure.

Toxicity profiles of TIL therapy need careful consideration.

There is potential for TIL therapy to be used in first-line treatment.

Sex-based differences in treatment outcomes are significant.

The trial design raises important regulatory questions.

Further research is needed to understand hormonal influences on treatment.

The results of this trial could change treatment paradigms in melanoma.

Sound Bites

"This is the first randomized study of cellular therapy."

"TIL therapy shows a near 50% response rate."

"The control arm has been criticized."

Chapters

00:00 Introduction to the TIL trial

04:08 Discussion on the efficacy of TIL therapy

09:12 Considerations for regulatory approval and future research

11:34 Analysis of toxicity in the TILT trial

15:46 Exploring the potential of TIL therapy in the first-line setting

20:12 Discussion on the feasibility of conducting larger trials with TIL therapy

23:42 Sex-based differences in the response to TIL therapy

27:35 Complexity of studying sex-based differences in cancer treatment

31:04 Conclusion and future implications of the TILT trial

33:07 Impressive Median Dose of Till Cells

33:33 Administration of High-Dose IL-2

Summary

In this episode of Melanoma Matters, host James Larkin uses his 1-800-Operator voice until co-host Sapna Patel reminds him to use his podium voice. There is a noisy wardrobe choice (SP) and a fact check of a fact check (JL).

Sapna and James have an in-depth conversation of the Checkmate 511 study, discussing its implications for treatment regimens in melanoma. They delve into the nuances of type 1 and type 2 errors, analyze the results of the study, and consider the long-term follow-up data. The conversation also explores global perspectives on treatment practices and the importance of understanding toxicity and efficacy in clinical settings.

Keywords

Checkmate 511, melanoma, type 1 error, type 2 error, treatment regimens, efficacy, toxicity, global perspectives, long-term follow-up, clinical practice

Takeaways

Checkmate 511 is a widely cited study in melanoma treatment.

Type one error relates to the alpha of the study, while type two error is related to sample size.

The study showed a lower incidence of grade 3 to 5 AEs with Nivo 3 - Ipi 1 compared to Nivo 1 -Ipi 3.

Long-term follow-up is crucial for understanding the efficacy of treatment regimens.

Global perspectives on treatment regimens vary, especially regarding reimbursement and labeling.

The study's findings have influenced practice in the U.S., despite a lack of formal publication.

Concerns remain about the efficacy of lower doses in specific patient populations, such as those with brain metastases.

The conversation highlights the importance of ongoing research and follow-up studies in melanoma treatment.

Understanding statistical errors is essential for interpreting clinical trial results.

The hosts express a desire for more comprehensive data and follow-up on the Checkmate 511 study.

Sound Bites

"This is a fact check of a fact check."

"Type one error is related to the alpha of a study."

"The incidence of grade 3 to 5 AEs was 34% with Nivo 3 -Ipi 1."

Chapters

00:00 Introduction and Volume Issues

04:50 Overview of Checkmate 511 Study

09:59 Concerns about Lack of Published Follow-Up Data

16:00 Demographics and Subgroups in Checkmate 511 Study

16:44 Implementation of Inverted Dosing Regimen Globally

19:01 Caution and Considerations with Inverted Dosing Regimen

23:45 Fact Check

25:08 Comparing Regimens in the BRAF Mutant Population

29:16 Fact-Checking 'Up in the Air'

29:50 Fact Check of a Fact Check (BRAF)